Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

CONTROVERSIAL STRATEGY: SELLING PATENTS TO A NATIVE AMERICAN TRIBE

Tangible IP's Latest IP Market Update

CQ Researcher - Prescription Drug Costs

CONTROVERSIAL STRATEGY: SELLING PATENTS TO A NATIVE AMERICAN TRIBE

Speaker Bios Do Not Delete - Foundry Events

Supreme Court's Arthrex decision creates more review for patent owners — and more questions - Medical Design and Outsourcing

Speaker Bios Do Not Delete - Foundry Events

Patent transfer to Mohawk tribe intended to stop generic drugs

Allergan CEO on patent deal: 'It wasn't desperation, it was tenacity

Prescription Drug Costs

Allergan plc

Selling Sovereignty: How Corporations Used Tribal Sovereign Immunity to Evade Regulation and Exploit Consumers - The Flaw

Allergan Mohawk Tribe Patent Deal